Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants.

Vidal F, López-Dupla M, Laguno M, Veloso S, Mallolas J, Murillas J, Cifuentes C, Gallart L, Auguet T, Sampériz G, Payeras A, Hernandez P, Arnedo M, Gatell JM, Richart C.

PLoS One. 2012;7(11):e47725. doi: 10.1371/journal.pone.0047725. Epub 2012 Nov 2.

2.

Low-density lipoprotein receptor genotyping enhances the predictive value of IL28B genotype in HIV/hepatitis C virus-coinfected patients.

Pineda JA, Caruz A, Di Lello FA, Camacho A, Mesa P, Neukam K, Rivero-juárez A, Macías J, Gómez-Mateos J, Rivero A.

AIDS. 2011 Jul 17;25(11):1415-20. doi: 10.1097/QAD.0b013e328348a7ac.

PMID:
21572301
3.

IL28B polymorphism, pretreatment CXCL10, and HCV RNA levels predict treatment response in racially diverse HIV/HCV coinfected and HCV monoinfected patients.

Zeremski M, Dimova RB, Makeyeva J, Sipley JD, Jacobson IM, Rennert H, Talal AH.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):9-16. doi: 10.1097/QAI.0b013e31828323c1.

PMID:
23274935
4.

Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.

Fernández-Rodríguez A, Rallón N, Berenguer J, Jiménez-Sousa MA, Cosín J, Guzmán-Fulgencio M, Restrepo C, Lopez JC, García-Álvarez M, Miralles P, Soriano V, Benito JM, Resino S.

AIDS. 2013 Jan 14;27(2):163-73. doi: 10.1097/QAD.0b013e32835c11e8.

PMID:
23135173
5.

Polymorphism of the IL28B gene (rs8099917, rs12979860) and virological response of Pakistani hepatitis C virus genotype 3 patients to pegylated interferon therapy.

Aziz H, Raza A, Ali K, Khattak JZ, Irfan J, Gill ML.

Int J Infect Dis. 2015 Jan;30:91-7. doi: 10.1016/j.ijid.2014.09.021. Epub 2014 Nov 20.

6.

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, Palomares JC, Mira JA, Martínez A, Roldán C, de la Torre J, Macías J.

Clin Infect Dis. 2010 Oct 1;51(7):788-95. doi: 10.1086/656235.

PMID:
20804372
7.

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.

Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR.

Aliment Pharmacol Ther. 2012 Jul;36(2):91-103. doi: 10.1111/j.1365-2036.2012.05131.x. Epub 2012 May 16.

8.

Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy.

Mandorfer M, Neukam K, Rivero A, Puoti M, Boesecke C, Baumgarten A, Grzeszczuk A, Zangerle R, Ernst D, Rockstroh JK, Trauner M, Pineda JA, Peck-Radosavljevic M, Reiberger T.

Antivir Ther. 2014;19(4):407-14. doi: 10.3851/IMP2717. Epub 2013 Dec 17.

PMID:
24342953
9.

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.

Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.

J Viral Hepat. 2014 Mar;21(3):178-88. doi: 10.1111/jvh.12128. Epub 2013 Jul 17.

PMID:
24438679
10.

Genetic polymorphisms of IL28b gene as predictors of response to dual therapy in genotypes 1 and 4-HCV and HIV/HCV-infected patients.

Sticchi L, Di Biagio A, Sartini M, Rappazzo E, Nicolini LA, Cenderello G, Valle C, Azzola E, Grasso A, De Leo P, Boldrini A, Setti M, Prinapori R, Lorusso C, Bruzzone B, Icardi G; Ligurian HIV Network.

New Microbiol. 2015 Oct;38(4):499-509. Epub 2015 Oct 20.

11.

Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.

Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.

Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14.

PMID:
24102823
12.

Expression of selected genes in liver biopsy specimens in relation to early virological response in patients with chronic hepatitis C with HCV mono- and HIV/HCV co-infection.

Jabłonowska E, Wójcik K, Koślińska-Berkan E, Szymańska B, Omulecka A, Piekarska A.

Arch Virol. 2014 Jun;159(6):1365-71. doi: 10.1007/s00705-013-1930-1. Epub 2013 Dec 24.

13.

Deciphering the interleukin 28B variants that better predict response to pegylated interferon-α and ribavirin therapy in HCV/HIV-1 coinfected patients.

de Castellarnau M, Aparicio E, Parera M, Franco S, Tural C, Clotet B, Martínez MA.

PLoS One. 2012;7(2):e31016. doi: 10.1371/journal.pone.0031016. Epub 2012 Feb 6.

14.

Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients.

Miyase S, Haraoka K, Ouchida Y, Morishita Y, Fujiyama S.

J Gastroenterol. 2012 Sep;47(9):1014-21. doi: 10.1007/s00535-012-0560-9. Epub 2012 Mar 2.

PMID:
22382633
15.

Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.

Neukam K, Camacho A, Caruz A, Rallón N, Torres-Cornejo A, Rockstroh JK, Macías J, Rivero A, Benito JM, López-Cortés LF, Nattermann J, Gómez-Mateos J, Soriano V, Pineda JA.

J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13.

PMID:
22173157
16.

Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype.

Vasconcelos LR, Moura P, do Carmo RF, Pereira LB, Cavalcanti Mdo S, Aroucha DC, Dutra RA, Pereira LM.

Hum Immunol. 2014 Aug;75(8):895-900. doi: 10.1016/j.humimm.2014.06.017. Epub 2014 Jun 30.

PMID:
24994464
17.

Short communication: serum-based assay accurately detects single nucleotide polymorphisms of IL28B and SOCS3 in HIV/hepatitis C virus-coinfected subjects.

Shaffer A, Hubbard JJ, Townsend K, Kottilil S, Polis MA, Masur H, Kohli A.

AIDS Res Hum Retroviruses. 2014 Aug;30(8):792-5. doi: 10.1089/AID.2014.0028. Epub 2014 Jul 14.

18.

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

Scherzer TM, Hofer H, Staettermayer AF, Rutter K, Beinhardt S, Steindl-Munda P, Kerschner H, Kessler HH, Ferenci P.

J Hepatol. 2011 May;54(5):866-71. doi: 10.1016/j.jhep.2010.08.024. Epub 2011 Jan 14.

PMID:
21145807
19.

IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients.

Payer BA, Reiberger T, Aberle J, Ferenci P, Holzmann H, Rieger A, Peck-Radosavljevic M; Vienna HIV-HCV study group.

Eur J Clin Invest. 2012 Jun;42(6):599-606. doi: 10.1111/j.1365-2362.2011.02623.x. Epub 2011 Nov 25.

PMID:
22117591
20.

Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.

Ogawa E, Furusyo N, Murata M, Ikezaki H, Ihara T, Hayashi T, Toyoda K, Taniai H, Okada K, Kainuma M, Hayashi J.

J Hepatol. 2012 Sep;57(3):534-40. doi: 10.1016/j.jhep.2012.04.027. Epub 2012 May 18.

PMID:
22613000

Supplemental Content

Support Center